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IMPORTANCE Manyadversehealthoutcomes are associatedwithobstructive sleepapnea (OSA).
OBJECTIVE To review primary care–relevant evidence on screening adults for OSA, test
accuracy, and treatment of OSA, to inform the US Preventive Services Task Force.
DATA SOURCES MEDLINE, Cochrane Library, EMBASE, and trial registries through October
2015, references, and experts, with surveillance of the literature through October 5, 2016.
STUDY SELECTION English-language randomized clinical trials (RCTs); studies evaluating
accuracy of screening questionnaires or prediction tools, diagnostic accuracy of portable
monitors, or association between apnea-hypopnea index (AHI) and health outcomes among
community-based participants.
DATA EXTRACTION AND SYNTHESIS Two investigators independently reviewed abstracts and
full-text articles. Whenmultiple similar studies were available, random-effects meta-analyses
were conducted.
MAIN OUTCOMES ANDMEASURES Sensitivity, specificity, area under the curve (AUC), AHI,
Epworth Sleepiness Scale (ESS) scores, blood pressure, mortality, cardiovascular events,
motor vehicle crashes, quality of life, and harms.
RESULTS A total of 110 studies were included (N = 46 188). No RCTs compared screening with
no screening. In 2 studies (n = 702), the screening accuracy of themultivariable apnea
prediction score followed by home portable monitor testing for detecting severe OSA
syndrome (AHI30 and ESS score >10) was AUC 0.80 (95% CI, 0.78 to 0.82) and 0.83 (95%
CI, 0.77 to 0.90), respectively, but the studies oversampled high-risk participants and those
with OSA and OSA syndrome. No studies prospectively evaluated screening tools to report
calibration or clinical utility for improving health outcomes. Meta-analysis found that
continuous positive airway pressure (CPAP) compared with shamwas significantly associated
with reduction of AHI (weightedmean difference [WMD], −33.8 [95% CI, −42.0 to −25.6];
13 trials, 543 participants), excessive sleepiness assessed by ESS score (WMD, −2.0 [95% CI,
−2.6 to −1.4]; 22 trials, 2721 participants), diurnal systolic blood pressure (WMD, −2.4 points
[95% CI, −3.9 to −0.9]; 15 trials, 1190 participants), and diurnal diastolic blood pressure
(WMD, −1.3 points [95% CI, −2.2 to −0.4]; 15 trials, 1190 participants). CPAPwas associated
with modest improvement in sleep-related quality of life (Cohen d, 0.28 [95% CI, 0.14 to
0.42]; 13 trials, 2325 participants). Mandibular advancement devices (MADs) and weight loss
programs were also associated with reduced AHI and excessive sleepiness. Common adverse
effects of CPAP andMADs included oral or nasal dryness, irritation, and pain, among others.
In cohort studies, there was a consistent association between AHI and all-cause mortality.
CONCLUSIONS AND RELEVANCE There is uncertainty about the accuracy or clinical utility of all
potential screening tools. Multiple treatments for OSA reduce AHI, ESS scores, and blood
pressure. Trials of CPAP and other treatments have not established whether treatment
reduces mortality or improves most other health outcomes, except for modest improvement
in sleep-related quality of life.
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O bstructive sleep apnea (OSA) (Table 1) has been associ-ated with an increased risk of many adverse healthoutcomes, including motor vehicle crashes,7-9 cognitive
impairment,10,11 cardiovascular events,12-14 atrial fibrillation,15
stroke,14,16 and mortality.8,13,14,17 However, there is controversy in
the literature regarding the extent to which OSA independently
contributes to various outcomes beyond the contributions of age,
body mass index (BMI), and other potential confounders. OSA is
common, with prevalence around 15% in men and 5% in women
(ages 30-70 years), based on either an apnea-hypopnea index
(AHI) of 15 or greater or an AHI of 5 or greater plus symptoms of
disturbed sleep.17,18
Screening to identify unrecognizedOSA followed by appropri-
ate treatment might improve sleep quality and normalize the AHI
and oxygen saturation levels to prevent adverse health outcomes.
Potential screeningstrategies includequestionnairesandclinicalpre-
diction tools that comprise combinations of subjective and objec-
tive findings. For people who screen positive, diagnostic polysom-
nography in a sleep facility or home-based testing with a portable
monitor could be used to determine whether they have OSA.
To informarecommendationbytheUSPreventiveServicesTask
Force (USPSTF), the evidence on test accuracy and benefits and
harms of screening and treatment for OSA in populations and set-
tings relevant to US primary care was reviewed.
Methods
Scope of Review
Detailed methods are available in the full evidence report at
https://www.uspreventiveservicestaskforce.org/Page/Document
/final-evidence-review152/obstructive-sleep-apnea-in-adults
-screening. Additional subgroup analyses (byOSA severity, baseline
sleepiness, and baseline blood pressure) and sensitivity analyses
conducted to explore heterogeneity or robustness of findings are
available in the full evidence report. Figure 1 shows the analytic
framework and key questions that guided the review.
Data Sources and Searches
We searched PubMed/MEDLINE, the Cochrane Library, and
EMBASE for English-language articles published through October
2015. ClinicalTrials.gov and the World Health Organization Interna-
tional Clinical Trials Registry Platform were also searched for
unpublished literature. The search strategies for PubMed and
Cochrane databases are detailed in the eMethods in the Supple-
ment. To supplement electronic searches, the reference lists of per-
tinent articles were reviewed, as well as all studies suggested by
reviewers or comments received during public commenting peri-
ods. Since October 2015, we conducted ongoing surveillance
through article alerts and targeted searches of high-impact journals
to identify major studies published in the interim that may affect
the conclusions or understanding of the evidence and therefore
the related USPSTF recommendation. The last surveillance was
conducted on October 5, 2016.
Study Selection
Two investigators independently reviewed titles, abstracts, and
full-text articles to determine eligibility using prespecified criteria
for each key question (KQ) (eTable 1 in the Supplement). Disagree-
ments were resolved by discussion. The review included English-
language studies of adults conducted in countries categorized
as “very high” on the Human Development Index. Only studies
rated as good or fair quality using predefined criteria and defini-
tions developed by the USPSTF and adapted for this topic (eTable 2
in the Supplement)20 were included. The review excluded stud-
ies of people with acute conditions (eg, stroke) that can trigger
onset of OSA and studies focused on screening, diagnosis, or treat-
ment of OSA among persons with rare conditions (eg, acromegaly)
for whom testing for OSA would be considered part of manage-
ment for their disease.
For the overarching question regarding direct evidence that
screening improveshealthoutcomes (KQ1) and thequestiononac-
curacyof clinical prediction toolsor screeningquestionnaires (KQ2),
studieswere required toenroll asymptomatic adultsorpersonswith
unrecognized symptoms of OSA; referral populations were not eli-
gible. ForKQ1, randomizedclinical trials (RCTs) comparing screened
withnonscreenedgroupswereeligible. ForKQ2, studies that evalu-
ated screening questionnaires or clinical prediction tools (alone or
followedbyhome-basedportablemonitoring) comparedwithover-
night polysomnography conducted in a sleep laboratory were eli-
gible.Studiesofpeople referredtosleep laboratoriesbecauseofcon-
cern for OSA were excluded, and studies in which only a subgroup
(usually thehighest-risk group)underwentpolysomnographywere
excluded because of concern for verification bias. Clinical predic-
tion tools were required to includemultiple factors.
For diagnostic test accuracy (KQ3) and harms associated with
screening and diagnostic tests (KQ7), referral populations were also
eligible (in addition to the populations eligible for KQ1 and KQ2).
For KQ3, good-quality, recent systematic reviews comparing por-
table monitors (Table 2 describes the types of monitors) with poly-
somnography conducted in a sleep laboratory were eligible. Mul-
tiple good-quality, recent, and relevant systematic reviews for KQ3
were identified; primary studies published after the search cutoffs
of the most recent systematic reviews were also included. For KQ7,
studies eligible for KQ1, KQ2, or KQ3 that reported false-positive
results leading to unnecessary treatment, anxiety, condition-
specific distress, or stigmawere eligible.
For benefits and harms of treatment (KQ4, KQ5, and KQ8),
RCTs enrolling people with a confirmed diagnosis of OSA were eli-
gible; studies could include asymptomatic adults, symptomatic
adults, or both. Studies evaluating continuous positive airway pres-
sure (CPAP), mandibular advancement devices (MADs), surgery,
and weight loss programs were included; other treatments were
not eligible (eg, oropharyngeal exercises). For KQ8, prospective
cohort studies with at least 100 participants that reported harms of
surgical interventions were also eligible.
For the association between AHI and health outcomes (KQ6),
prospective cohort studies that followedupparticipants for at least
1 yearwere included. Studieswere excluded that focused primarily
on central sleep apnea, enrolled patients hospitalized for acute
events, enrolled patients in a periprocedural period, or did not ad-
dress potential confounding.
Data Extraction andQuality Assessment
For each included study, one investigator extracted information
about thepopulations, testsor treatments, comparators, outcomes,
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settings, and designs, and a second investigator reviewed for com-
pletenessandaccuracy.Two independent investigatorsassessedthe
quality of studies as good, fair, or poor. Disagreements were re-
solved by discussion.
Data Synthesis and Analysis
Findings for each question were summarized in tabular and
narrative form. To determine whether meta-analyses were appro-
priate, the clinical and methodological heterogeneity of the studies
was assessed following established guidance.22 When multiple
similar studies were available, quantitative synthesis was con-
ducted with random-effects models using the inverse-variance
weighted method (DerSimonian and Laird) to estimate pooled
effects.23 For all quantitative syntheses, the I2 statistic was calcu-
lated to assess statistical heterogeneity in effects between
studies.24,25 Quantitative analyses were conducted using Compre-
hensive Meta-Analysis version 3.3 (Biostat Inc) and Stata version 14
(StataCorp). Statistical significance was assumed when 95%
CIs of pooled results did not cross the null (ie, 0 or 1, depending
on the effect measure). All testing was 2-sided. This review
covered a wide range of outcome measures and instruments;
keymeasures and questionnaires are summarized in eTable 3 in the
Supplement.
For KQ4 and KQ5 the weighted mean difference (WMD)
between intervention and control was calculated for continuous
outcomes; when multiple scales were combined in a single meta-
analysis (for sleep-related quality of life), we used the standard-
ized mean difference, Cohen d. For Cohen d, a value of 0.20 is
often interpreted as a small effect size, 0.50 as a medium effect
size, and 0.80 as a large effect size.26 For meta-analyses of CPAP
and MAD treatments, pooled estimates were calculated sepa-
rately for studies using sham controls and those using other con-
trols. Parallel trials and crossover trials were combined, but sub-
group analyses were conducted to explore whether findings
differed by this design feature.
For KQ6, we conducted meta-analyses of adjusted hazard ra-
tios (HRs) and95%confidence intervals for all-causemortality. The
HRswereconverted toa logscale, andstandarderrorsof the logHRs
were calculated to normalize distributions and stabilize variances.
Themetan command with the eform command in Stata was then
used toestimatepooledHRs.AnalyseswerebyAHI thresholds cor-
responding to OSA severity categories.
Results
Atotal of 110studies (127articles)withN = 46 188participantswere
included (Figure 2). Individual study quality ratings are reported in
eTables 4 through 12 in the Supplement. The main results for each
key question are summarized below; additional details and analy-
ses are available in the full evidence report.27
Benefits of Screening
Key Question 1a. Does screening for OSA in adults improve health
outcomes?
KeyQuestion 1b.Does theevidencediffer for subgroupsdefinedby
age, sex, BMI, or OSA severity?
No eligible studies were identified.
Accuracy of Clinical Prediction Tools
or Screening Questionnaires
KeyQuestion 2a.What is the accuracy of currently existing clinical
prediction tools or screening questionnaires in identifying persons
in the general population who are more or less likely to have OSA?
Key Question 2b.What is the accuracy of multistep screening ap-
proaches, such as using a questionnaire or prediction tool followed
byovernighthome-based testing, in identifyingpersons in thegen-
eral population who are more or less likely to have OSA?
Three studies were included (Table 3).28-30 One evaluated the
Berlin Questionnaire,28 and 2 evaluated the Multivariable Apnea
Prediction (MVAP) score, alone andwhen followed by in-home por-
table monitoring.29,30 Details of the questions and scoring are
reported in the eBackground in the Supplement.
The study evaluating the Berlin Questionnaire randomly
sampled Norwegians from the National Population Register (55%
response rate: 16 302/29 258).28 Of those completing the ques-
tionnaire, 24%were classified as high risk and 518 had undergone
in-hospital polysomnography. Of those 518, mean age was 48
years, 45% were female, mean BMI was 28 (calculated as weight
in kilograms divided by height in meters squared), and median
AHI was 6.4. Although the group undergoing polysomnography
oversampled high-risk participants (70% were high risk), the
analyses adjusted for bias in the sampling to report estimated
screening properties for the general population. The study found
suboptimal screening properties (for AHI 5: sensitivity, 37.2%;
specificity, 84%; for AHI15: sensitivity, 43%; specificity, 79.7%)
Table 1. Obstructive Sleep Apnea–Related Terms and Definitions
Term Definition
Apnea Cessation of airflow for at least 10 s1,2
Hypopnea Reduction in airflow by at least 30% for at least 10 s
with decrease in oxygen saturation
AHIa,b,c Number of apneas and hypopneas per h of sleep
OSAd
Mild1,3 AHI ≥5 to <15
Moderate1,3 AHI ≥15 to <30
Severe1,3 AHI ≥30
Obstructive sleep
apnea syndrome
AHI ≥5 with evidence of daytime sleepiness1,4,5
Abbreviations: AHI, apnea-hypopnea index; OSA, obstructive sleep apnea.
a OSA occurs when airflow is absent or substantially reduced because of upper
airway obstruction but breathing effort persists. OSA severity is usually
categorized using the AHI as assessed by a sleep study (polysomnography).
b The respiratory disturbance index is a measure similar to the AHI, but it also
includes the number of respiratory effort–related arousals per hour of sleep
(in addition to apnea events and hypopnea events).
c The AHI incorporates both obstructive and central apnea and hypopnea
events, and significantly elevated AHI is not synonymous with OSA (because it
can indicate OSA, central sleep apnea, or mixed sleep apnea—with both OSA
and central sleep apnea).
dBoth the Centers for Medicare &Medicaid Services and the American
Academy of SleepMedicine define OSA as an AHI or respiratory disturbance
index of at least 15 events per hour, or at least 5 events per hour with
documented symptoms (eg, excessive daytime sleepiness, impaired
cognition, mood disorders, or insomnia; waking up breath-holding,
gasping, or choking; or documented hypertension, ischemic heart disease,
or history of stroke).4,6
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(Table 4). The unadjusted analyses showed much better sensitiv-
ity but worse specificity (for AHI5: sensitivity, 79.4%; specific-
ity, 40.5%; for AHI 15: sensitivity, 82.8%; specificity, 34.9%),
likely reflecting spectrum bias.
Both studies assessing the MVAP included highly selected
patients.29,30 One study evaluated Medicare recipients (n = 452),
most (74%) of whom had daytime sleepiness.29 The percentage
with OSA was not reported, but 27% had obstructive sleep apnea
syndrome (OSAS), defined as AHI 5 or greater and Epworth Sleepi-
ness Scale (ESS) score greater than 10. The other study evaluated
patients with hypertension (n = 250).30 Eighty percent of partici-
pants had OSA (AHI 5); of those, 22% had moderate and 25%
had severe OSA; 25% of all participants had OSAS. Mean ages of
participants were 7129 and 5330 years; 60% to 64% were non-
white; andmean BMIs were 30 to 32, respectively. Key quality limi-
tations included concern for attrition bias30 and moderate concern
for selection bias or spectrum bias (with high prevalence of OSA,
OSAS, and/or daytime sleepiness among those undergoing
polysomnography).29,30
Both studies reported operating characteristics of MVAP to
predict severe OSAS (AHI30 and ESS score >10) (Table 4). The
study of Medicare recipients reported reasonable discrimination
Figure 1. Analytic Framework and Key Questions
Key questions
a. Does screening for obstructive sleep apnea (OSA) in adults improve health outcomes?
b. Does the evidence on screening for OSA in adults differ for subgroups defined by age, sex, body mass index (BMI), or OSA severity?
1
a. Does treatment with CPAP, mandibular advancement devices, surgery, or weight loss programs improve health outcomes in persons with OSA?
b. Do the benefits of treatment (for health outcomes) differ for subgroups defined by age, sex, BMI, or OSA severity?
5
a. Are there harms associated with screening or diagnostic testing for OSA?
b. Do the harms of screening or diagnostic testing differ for subgroups defined by age, sex, or BMI?
7
a. Are there harms associated with treatment of OSA?
b. Do the harms of treatment differ for subgroups defined by age, sex, BMI, or OSA severity?
8
Is there an association between AHI and health outcomes?6
a. What is the accuracy and reliability of diagnostic tests for OSA?
b. Do the accuracy and reliability of diagnostic tests for OSA differ for subgroups defined by age, sex, or BMI?
3
a. What is the accuracy of currently existing clinical prediction tools or screening questionnaires in identifying persons in the general population
who are more or less likely to have OSA?
b. What is the accuracy of multistep screening approaches, such as using a questionnaire or prediction tool followed by overnight home-based
testing, in identifying persons in the general population who are more or less likely to have OSA?
2
a. How much does treatment with continuous positive airway pressure (CPAP), mandibular advancement devices, surgery, or weight loss
programs improve intermediate outcomes (ie, the apnea-hypopnea index [AHI], blood pressure, or sleepiness) in persons with OSA?
b. Do the benefits of treatment (for intermediate outcomes) differ for subgroups defined by age, sex, BMI, or OSA severity?
4
Treatment
Asymptomatic
adults
Screening
to identify
higher risk
Mortality
Quality of life
Motor vehicle crashes
Cardiovascular events
Cerebrovascular events
Heart failure
Headaches
Cognitive impairment
Health outcomes
1
5
2 4 6
Harms of
treatment 
8
Diagnostic
test
3
Harms of
testing
7
Harms of
screening 
7
Change in AHI
Change in blood pressure
Daytime somnolence or
sleepiness
OSA
Adults with
increased
risk for OSA
Evidence reviews for the US Preventive Services Task Force (USPSTF) use an
analytic framework to visually display the key questions that the reviewwill
address to allow the USPSTF to evaluate the effectiveness and safety of a
preventive service. The questions are depicted by linkages that relate
interventions and outcomes. A dashed line indicates health outcomes that
follow an intermediate outcome. Further details are available from the USPSTF
procedure manual.19,20
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(area under the curve [AUC], 0.78 [95% CI, 0.71 to 0.85]), whereas
the other study found inadequate discrimination (AUC, 0.68 [95%
CI, 0.67 to 0.70]). An AUC less than 0.70 has been considered to
indicate inadequate discrimination.31,32 Both studies also reported
measures of discrimination for the MVAP score followed by
in-home portablemonitoring (Table 4).29,30 The studies byMorales
et al29 and Gurubhagavatula et al30 reported characteristics to pre-
dict severe OSAS using different portable monitor–based AHI cut-
offs (ie, 1529 and 1830). Both found better operating characteristics
when using MVAP followed by in-home portable monitoring (AUC,
0.80-0.83) than when usingMVAP alone.29,30
The study of participants with hypertension also reported op-
eratingcharacteristicsofMVAPandMVAPfollowedby in-homepor-
tablemonitoring topredict anyOSAS (AHI5andESSscore>10).30
It found inadequate discrimination (Table 4).
Diagnostic Accuracy and Reliability of PortableMonitors
Key Question 3a.What is the accuracy and reliability of diagnostic
tests for OSA?
KeyQuestion 3b.Do the accuracy and reliability of diagnostic tests
for OSA differ for subgroups defined by age, sex, or BMI?
We included 3 studies evaluating type II portable monitors,
1 systematic review and 2 subsequent studies evaluating type III
portable monitors, and 1 systematic review and 14 subsequent
studies evaluating type IV portable monitors. Study participants
were generally those referred to sleep units for suspected sleep
apnea. No studies were found that identified participants via
screening to provide evidence on asymptomatic patients or those
with unrecognized symptoms, although detailed reporting of rea-
sons for referral was generally limited. Details of individual study
characteristics and results are provided in the eResults and eTables
13 through 22 in the Supplement.
Table5 summarizes the rangeof sensitivities, specificities, and
AUCs by type of portable monitor for AHI thresholds of 5, 15, and
30. The best evidence comes from systematic reviews that re-
ported sensitivities of 93% (pooled estimate from in-home stud-
ies) and96% (pooled estimate from in-laboratory studies) for type
III portable monitors and at least 85% for type IV portable moni-
tors for detecting any OSA (AHI5).21 Corresponding specificities
were 60%and 76% for in-home and in-laboratory type III portable
monitors, respectively, and ranged from 50% to 100% for type IV
portable monitors.21 Sensitivities decreased and specificities in-
creased for detecting moderate or greater OSA (AHI 15) or se-
vere OSA (AHI30). The ranges of sensitivity and specificity re-
ported across studies for type IVmonitors were wide.
Benefits of Treatment
Key Question 4a. How much does treatment with CPAP, MADs,
surgery, or weight loss programs improve intermediate outcomes
(AHI, blood pressure, or daytime sleepiness) in persons with OSA?
Key Question 4b. Do the benefits of treatment (for intermediate
outcomes) differ for subgroups defined by age, sex, BMI, or
OSA severity?
Includedwere76RCTs:56trialsevaluatedCPAP(eTables23and
24 in the Supplement),53-112 10 trials evaluatedMADs (eTable 25 in
the Supplement),98,105,113-122 6 trials evaluated surgical interven-
tions (eTable 26 in the Supplement),123-128 and 6 trials evaluated
weight loss, diet, and exercise programs (eTable 27 in the
Supplement).129-138 None of the trials focused on participants who
were screen-detected in primary care settings.
Continuous Positive Airway Pressure
Most studies identified participants from sleep clinics or referrals.
Duration of treatment ranged from 1 week to 4 years. Most trials
lasted for 12 weeks or less, but 5 trials treated participants for 24
weeks or longer,70,96,97,99,107 including 2 that followed up partici-
pants for 52 weeks96,107 and 1 that did so for a median of 4 years.97
Mean agewas 40s to 50s inmost studies (range, 42-71). Themajor-
ity of participants in most trials were men, with 44 trials reporting
that less than one-third of participants were women. Mean BMI
was 30 to 35 in most trials (range, 27-39). Mean or median baseline
AHI (or similar measure) was in the severe OSA range (AHI30)
formore than 75%of trials; 8 trials reported it in themoderate OSA
range,75,76,80,87,98,103,105,107 and 4 reported it in the mild OSA
range.91,99,101,108 Mean baseline ESS score was 10 or more in 33
trials, indicating excessive daytime sleepiness. Ten trials reported
Table 2. Classification ofMonitors Used for Diagnosis of Obstructive Sleep Apneaa
Type Portability
No. of Channels
(ie, Physiologic Measures) Typical Parameters
≥2 Airflow
or Effort Channels Measures AHI
I Facility-based ≥7 (usually 12-16) EEG, EOG, EMG, ECG/heart rate, airflow
(nasal, oral, or both), respiratory effort
(thoracic or abdominal movement),
SaO2, body position, leg movement, snoring
Yes Yes
II Portable ≥7 EEG, EOG, EMG, ECG or heart rate, airflow, respiratory
effort (thoracic or abdominal movement), SaO2b
Yes Yes
III Portable ≥4 (usually 4-7) Ventilation, airflow, or both; respiratory effort
(thoracic or abdominal movement);
ECG or heart rate; SaO2
Yes No
IV Portable ≥1 (usually 1-3) Usually SaO2; may include additional channels,
provided the monitor does not qualify as type IIIc,d
No No
Abbreviations: AHI, apnea-hypopnea index; ECG, electrocardiogram;
EEG, electroencephalogram; EMG, electromyogram; EOG, electro-oculogram;
SaO2, arterial oxygen saturation.
a Modified,with permission, fromaprevious systematic review21 (EthanBalk,MD,
MPH, BrownUniversity School of Public Health, written communication,
October 5, 2015).
bHeart rate is allowed in place of electrocardiogram in type II portable monitors.
Type II monitors usually measure the same channels as type I monitors
but are portable.
c Unlike other monitor types that measure SaO2 by oximetry, type IVmonitors
maymeasure SaO2 by oximetry, airflow, or both.
d Parameters that are more commonly measured by type IV portable monitors
include but are not limited to snoring, body position, leg movement,
peripheral arterial tone, and plethysmography.
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a mean baseline ESS score less than 10,55,59,63,72,87,96,97,99,103,106
and 13 trials did not report baseline ESS score.
For AHI, trials reporting sufficient data for meta-analysis fol-
loweduppatients for 12weeksor less.Themeta-analyses foundthat
CPAP was associated with reduction of AHI compared with sham
CPAP (WMD, −33.8 [95% CI, −42.0 to −25.6]; 13 trials, 543 partici-
pants) and other controls (WMD, −25.8 [95% CI, −34.2 to −17.5];
6 trials, 294 participants) (eFigures 1 and 2 in the Supplement). All
individual studies reported end-point AHI values of 10 or less for
CPAP-treated groups, andmost were normal (<5).
Thirty-four trials reported sufficient ESS data to include in
meta-analyses. Most were 12 weeks or less in duration; 5 followed
up participants for 24 weeks,70,99 48 to 52 weeks,96,107 or
longer.97 The meta-analyses found that CPAP was associated with
reduction of ESS scores compared with sham CPAP (WMD, −2.0
[95% CI, −2.6 to −1.4]; 22 trials, 2721 participants) and other con-
trols (WMD, −2.2 [95% CI, −2.8 to −1.6]; 12 trials, 2488 partici-
pants) (eFigures 3 and 4 in the Supplement). Among the 27 trials
with mean or median baseline ESS scores of 10 or greater (mean
baseline ESS score was 12.7 among them) or those that provided
subgroup analyses for the participants with excessive sleepiness,
the subgroup analysis found a similar result (WMD, −2.4 [95% CI,
−2.9 to −1.9]) (eFigure 5 in the Supplement). Twenty-three of
those 27 trials reported mean end-point ESS scores less than 10
for the CPAP group (mean end-point ESS score for the 23 trials
was <8).
Twenty-nine trials reported sufficient blood pressure data to
include in meta-analyses. Blood pressure outcomes were reported
in a variety of ways; most commonly, diurnal systolic and diurnal
diastolic blood pressure. Most trials were 12 weeks or less in dura-
tion; 3 followed up participants for 24 to 52 weeks.96,99,107 The
meta-analyses found that CPAP was associated with reduction of
diurnal systolic blood pressure by 2 to 3 points (WMD, −2.4 [95%
CI, −3.9 to −0.9]; 15 trials, 1190 participants) (eFigure 6 in the
Supplement) and diurnal diastolic blood pressure by more than 1
point (WMD, −1.3 [95%CI, −2.2 to −0.4]; 15 trials, 1190 participants)
(eFigure 7 in the Supplement) compared with sham CPAP. Reduc-
tion in 24-hour mean arterial pressure was about 2 points with
Figure 2. Summary of Evidence Search and Selection
8398 Citations excluded based on review
of title and abstract
0 Studies included
for KQ1
3 Studies (3
articles) included
for KQ2
21 Studies (22
articles) included
for KQ3
76 Studies (88
articles) included
for KQ4
50 Studies (58
articles) included
for KQ5
11 Studies (12
articles) included
for KQ6
0 Studies included
for KQ7
22 Studies (26
articles) included
for KQ8
1316 Full-text articles excluded
14 Non-English
31 Ineligible publication type
172 Ineligible population
161 Ineligible test or intervention
266 Ineligible comparator
168 No outcome of interest
2 Ineligible setting
244 Ineligible study design
36 Ineligible country
8 Full text unavailable
22 Abstract only a
27 Title only a
1 Article retracted
33 Poor quality
131 Superseded by other included
article
10 033 Citations identified through
literature database searches
110 Studies (127 articles) included
1206 Citations identified through other
sources (eg, reference lists, trial
registries, previous reviews, expert
reviewers)
9841 Titles and abstracts screened
after duplicates removed
1443 Full-text articles assessed
for eligibility
a Insufficient information to assess risk of bias.
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CPAP comparedwith shamCPAP (WMD, −2.1 [95%CI, −3.2 to −1.0];
5 trials, 621 participants) (eFigure 8 in the Supplement).
Among the6studies thatprovided results forparticipantswith
uncontrolled hypertension,60,62,66,87,96,106 the subgroup analysis
foundsimilar but slightly larger effect sizes (eFigures9and 10 in the
Supplement); reductions of −2.5 points for diurnal systolic blood
pressure, −2.1 points for diurnal diastolic blood pressure, and −2.7
points for 24-hour mean arterial pressure.
Mandibular Advancement Devices
Six of the 10 included RCTs compared MADs with sham
devices.113-117,120 Comparators used in other RCTs were a placebo
tablet,98 no treatment,121,122 and conservative management with
weight loss.105All studies recruitedparticipantswith knownor sus-
pectedOSAfromspecialty clinics. Treatmentdurations ranged from
4to 12weeks formost studies,but 1 lastedonly 1week121 and 1 lasted
24 weeks.114 Mean age of participants ranged from 45 to 59 years.
Themajorityofparticipants in all trialsweremen,withwomencom-
prising 17% to 25% of participants in the 9 trials reporting sex. All
studies includedparticipantswithmild tomoderateOSA, and6also
includedparticipantswith severeOSA.105,113,116,117,120,121Meanbase-
line ESS scores ranged from 11 to 14.
The meta-analyses found that MADs were associated with
greater improvement in AHI than sham devices (−12.6 [95% CI,
−15.5 to −9.7]; 6 trials, 307 participants) and other controls (−8.2
[95% CI, −13.9 to −2.5]; 5 trials, 358 participants) (eFigures 11 and
12 in the Supplement). MADs were also associated with reduction
of ESS scores compared with sham devices (−1.5 [95% CI, −2.8 to
−0.2]; 5 trials, 267 participants) and other controls (−1.7 [95% CI,
−2.2 to −1.2]; 5 trials, 358 participants) (eFigures 13 and 14 in the
Supplement).
Five trials reported sufficient blood pressure data for
meta-analysis.105,113,115,116,119 The meta-analyses found no statisti-
cally significantdifferencesbetweenMADsandcomparators forany
of the blood pressure measures (eFigures 15 through 20 in the
Supplement).
Airway Surgery and Bariatric Surgery
Six trials each evaluated a different surgical technique, including
radiofrequency surgery of the soft palate,123 temperature-
controlled radiofrequency tissue ablation,128 uvulopalatopharyn-
goplasty,124 laser-assisteduvulopalatoplasty,126 septoplasty,127 and
bariatric surgery125 (eTable 26 in the Supplement). Sample sizes
ranged from 32123 to 67.124 Overall, the trials provided limited evi-
denceandfoundnosignificant reduction inAHI,ESSscores,orblood
pressure, with the exception of the trials of uvulopalatopharyngo-
plasty124and laser-assisteduvulopalatoplasty,126whichfoundgreater
reductions inAHI for surgery than for no treatment (−26.4 [95%CI,
−36.2 to −16.6] and−10.5 [95%CI, −16.9 to−4.1], respectively). Fur-
ther details of the characteristics and results of trials that evalu-
ated surgical interventions are provided in the eResults and eFig-
ures 21 and 22 in the Supplement.
Weight Loss, Diet, and Exercise Interventions
Six trials evaluated weight loss programs (eTable 27 in the
Supplement).129-138 Each trial evaluated a different intervention
Table 3. Characteristics of Included Studies Assessing Accuracy of Clinical Prediction Tools or Screening Questionnaires (Key Question 2)a
Source No. Study Design Participants
Questionnaire/
Tool Name
Age,
Mean
(Range)
%
Female
%
Non-White
BMI,
Mean (SD)
AHI,
Mean (SD)
Hypertension,
% OSA, %
Hrubos-Strom
et al,28 2011
Norway
518b Cross-sectional Randomly
drawn from
national
population
register
BQ
(Norwegian
translation)
48
(NR)
45 NR 28
(4.8)
Median, 6.4
(Q1-Q3,
1.7-18.3)
27 NR
Morales
et al29 2012
United States
452 Cross-sectional Medicare
recipients
from greater
Philadelphia
metro region,
most with
some daytime
sleepinessc
MVAP score
and MVAP
plus AHI
from
in-home
portable
monitor
71
(NR)
70 64 30
(6.2)
NR NR Any OSA: NR
Any OSAS
(AHI≥5
and ESS>10): 27d
Gurubhagavatula
et al,30 2013
United States
250 Cross-sectional Those with
hypertension
from internal
medicine
practices and
a hypertension
clinice
MVAP score
and MVAP
plus AHI
from
in-home
portable
monitor
53
(NR)
20 60 32.1
(7.4)
22.5
(22.9)
100 Of the 79%
who had
in-laboratory
polysomnography:
Any OSA: 80f
% OSAS: 25g
Abbreviations: AHI, apnea-hypopnea index; BMI, bodymass index; BQ, Berlin
Questionnaire; ESS, Epworth Sleepiness Scale; MVAP, Multivariable Apnea
Prediction; NR, not reported; OSA, obstructive sleep apnea; OSAS, obstructive
sleep apnea syndrome.
a All 3 studies in table were of fair quality.
b The data in this row describe the 518 participants who underwent
polysomnography. The 518 were a subset of the larger study population of
16 302who completed the BQ. For the 16 302, mean age was 48 years, 53%
were female, mean BMI was 26 (SD, 4.3), and 14% had hypertension.
c Seventy-four percent met their definition of daytime sleepiness
(frequency of sleepiness, based on whether they had a problem staying
awake, of every day or several [3] days per week); 32% had ESS scores
greater than 10 (Indira Gurubhagavatula, MD, MPH, Perelman School of
Medicine, University of Pennsylvania, written communication, July 2015).
dMild (AHI 5-15 and ESS score >10), 9%; at least moderate (AHI15 and ESS
score >10), 17%; moderate (AHI 15-30 and ESS score >10), 8%; severe
(AHI30 and ESS score >10), 8%.
e Required to have blood pressure of 140/90mmHg or higher or to be taking
antihypertensive medications.
f Mild, 34%;moderate, 22%; severe, 25%.
g At least mild (AHI5 and ESS score >10), 25%; severe (AHI30 and ESS
score >10), 7.6%.
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and control—2 interventions focused primarily on exercise,129,133 2
focused primarily on diet,132,136 and 2 used multicomponent life-
style interventions (exercise, diet, and psychoeducation).130,135
Sample sizes ranged from 26129 to 264.130 Participants were gener-
ally identified from sleep clinics, referrals, and advertisements.
Duration of follow-up was 4 to 26 weeks for 4 of the trials; the
other 2 trials followed up participants for 4 or 5 years.130,136 Mean
age ranged from 47 to 61 years. Mean BMI ranged from 30 to 40.
Mean AHI was in the moderate to severe OSA range for 4 of the
trials, in the mild range for 1 trial,136 and was moderate to severe
but controlled with CPAP use in 1 trial.135 Mean baseline ESS score
was 10 or more in 2 trials,129,136 less than 10 in 3 trials,132,133,135 and
not reported for 1 trial.130 The weight loss achieved by intervention
groups was very limited in 1 trial (−0.3 kg),133 modest in another
(−2.3 kg),135 and larger in the rest (−5 kg to −20 kg).130,132,138
Four of the 5 trials129,130,132,133,138 reporting AHI found statisti-
cally significant reductions, ranging from−5.8 (95%CI, −9.7 to−1.9)
to −23 (−30.1 to −15.9) (eFigure 23 in the Supplement). The trial re-
porting the largest reduction in AHI (a reduction nearing that
achievedbyCPAP)alsoreportedamuch largerweight reductionthan
other trials (−20 kg over 9 weeks from a very low energy diet).132
The meta-analysis for AHI found aWMD of −12.4 (95% CI, −19.4 to
−5.5).Threeof the4trials129,132,133,138 reportingESSscores foundsta-
tistically significant reductions, ranging from −3 to −7. The meta-
analysis found that weight loss interventionswere associatedwith
improvement in ESS scores comparedwith controls (−3.4 [95%CI,
−5.9 to −1.0]; 4 trials, 213 participants) (eFigure 24 in the Supple-
ment). Three trials reportedbloodpressureoutcomesand foundno
significantdifferencesbetweentreatmentandcontrolgroups.134-136
Benefits of Treatment
Key Question 5a. Does treatment with CPAP, MADs, surgery, or
weight lossprograms improvehealthoutcomes inpersonswithOSA?
KeyQuestion5b.Dothebenefitsof treatment (forhealthoutcomes)
differ for subgroups definedby age, sex, BMI, orOSA severity?
Included were 50 RCTs (eTables 25 through 31 in the Supple-
ment) that reported at least 1 eligible health outcome (47 of these
were included in KQ4). Most were short-term RCTs (12 weeks or
less) that reported zero or few deaths. None focused on screen-
detected patients from primary care settings. The main findings
Table 4. Results of Included Studies: Accuracy of Screening Questionnaires and Clinical Prediction Tools (Key Question 2)
Source
Questionnaire/
Tool Name and Cutoff Value
(95% CI)
Calibration OtherSensitivity Specificity AUROC
Hrubos-Strom
et al,28 2011
BQ to predict AHI ≥5
Cutoff = BQ high risk vs
low riska
37.2
(36.0-38.4)
84.0
(83.2-84.7)
NR NR PPV, 61.3
(95% CI, 59.7-62.9)
NPV, 66.2
(95% CI, 65.3-67.1)
LR+, 2.3
(95% CI, 2.2-2.5)
LR−, 0.8
(95% CI, 0.7-0.8)
BQ to predict AHI ≥15
Cutoff = BQ high risk vs
low riska
43.0
(41.2-44.8)
79.7
(79.0-80.5)
NR NR PPV, 33.5
(95% CI, 32.0-35.0)
NPV, 85.5
(95% CI, 84.8-86.1)
LR+, 2.1
(95% CI, 2.0-2.3)
LR−, 0.7
(95% CI, 0.7-0.7)
Morales
et al,29 2012
MVAP to predict severe OSAS
(AHI ≥30 and ESS score >10)
Cutoff = 0.49
90.0
(NR)
64.4
(NR)
0.78
(0.71-0.85)
NR LR−, 0.141
NPTP, 1.1%
(95% CIs, NR)
MVAP + uAHI to predict severe
OSAS (AHI ≥30 and ESS score
>10)
Cutoff = uAHI 15b
90.9
(NR)
75.7
(NR)
0.83
(0.77-0.90)
NR LR−, 0.120
NPTP, 1.0%
(95% CIs, NR)
Gurubhagavatula
et al,30 2013
MVAP to predict severe OSAS
(AHI ≥30 and ESS score >10)
Cutoff = 0.483
91.5
(NR)
43.9
(NR)
0.68
(0.67-0.70)
NR LR−, 0.190
NPTP, 0.015
(95% CIs, NR)
MVAP to predict any OSAS
(AHI ≥5 and ESS score >10)
Cutoff = 0.559
69.4
(NR)
56.5
(NR)
0.61
(NR)
NR LR−, 0.524
NPTP, 0.148
(95% CIs, NR)
MVAP + uAHI to predict
severe OSAS (AHI ≥30
and ESS score >10)
Cutoff = uAHI 18b
88.2
(NR)
71.6
(NR)
0.80
(0.78-0.82)
NR LR−, 0.162
NPTP, 0.015
(95% CIs, NR)
MVAP + uAHI to predict
any OSAS (AHI ≥5
and ESS score >10)
Cutoff = uAHI 13.5b
80.5
(NR)
54.0
(NR)
0.67
(NR)
NR LR−, 0.349
NPTP, 0.104
(95% CIs, NR)
Abbreviations: AHI, apnea-hypopnea index; AUROC, area under
the receiver operating characteristic curve; BQ, Berlin Questionnaire;
ESS, Epworth Sleepiness Scale; LR, likelihood ratio; MVAP, multivariable
apnea prediction; NPTP, negative posttest probability; NPV, negative
predictive value; NR, not reported; OSAS, obstructive sleep apnea
syndrome; PPV, positive predictive value; uAHI, unattended AHI from
home sleep test.
a Estimates were based on a simulatedmodel that adjusted for oversampling
of BQ high-risk participants (not just based on findings for the 518 in the
clinical sample).
b Two-stage process using MVAP for everyone and then home testing to
determine AHI for those with an intermediate MVAP score.
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are summarized below; additional outcomes for which there were
limited data are shown in eTables 29 through 31 in the Supplement
and are summarized in the full report.
Continuous Positive Airway Pressure
Thirty-f ive RCTs compared CPAP with sham
CPAP53,55,62-65,67,70,72,75,76,79,80,82,86-89,91,93,97,139 or another
control.95,97-103,105,107-109,140,141 Most trials followed up partici-
pants for 12 weeks or less; 4 trials measured outcomes over 24
weeks or longer,70,97,99,107 including 1 that followed up participants
for a median of 4 years.97 Most enrolled populations with a mean
age in the 40s to 50s (range, 42-71 years). Mean BMI was 30
to 35 in most trials (range, 27-37). Mean or median baseline AHI
(or similar measure) was in the severe OSA range (AHI 30) for
more than half of trials; 9 trials reported it in the moderate OSA
range,75,76,80,87,98,103,105,107,140 and 5 reported it in the mild
OSA range.91,99,101,108,141
Thirty-oneRCTs reportedonmortality (eTable29 in theSupple-
ment); most (29 RCTs) reportedmortality rates at 12 weeks or less.
Most(27RCTs,2211 totalparticipants) reportednodeaths inanystudy
group.53,55,62,64,65,67,72,75,76,79,80,82,87-89,91,95,98,100-103,105,108,109,140,141
Two trials (462 total participants) reported 1 death, either in the
CPAP group99 or in the sham CPAP group at 12 weeks.63 Two RCTs
assessed mortality over a longer duration.70,97 One (n = 1105)
reported 2 deaths in each study group over 24 weeks.70 The other
(n = 723) reported 8 deaths in the CPAP group and 3 in the control
group over about 4 years (incidence density ratio, 2.6 [95% CI,
0.70 to 11.8]; P = .16).97
Twenty-two RCTs reported a variety of quality-of-life mea-
sures (eTable 29 in the Supplement). The meta-analysis found no
difference between CPAP and comparators in the change from
baseline 36-Item Short Form Health Survey (SF-36) mental com-
ponent score (WMD, 1.2 [95% CI, −0.8 to 3.2]; 8 trials, 1039 par-
ticipants) (eFigure 25 in the Supplement). The meta-analysis
found that CPAP was associated with improved SF-36 physical
component score compared with sham CPAP over 12 weeks or
less (WMD, 2.3 [95% CI, 0.2 to 4.4]; 7 trials, 648 participants)
(eFigure 26 in the Supplement).
Thirteen RCTs assessed sleep-related quality of life—6 using
the Sleep Apnea Quality of Life Index (SAQLI)89,93,99,105,107,142
and 7 using the Functional Outcomes of Sleep Questionnaire
(FOSQ).55,76,79,86,91,98,102 Most reported outcomes at 12 weeks or
less; 2 reported outcomes at 24 weeks (or 6 months)99,142 and 1
at 52 weeks.107 The meta-analysis (combining SAQLI and FOSQ
scores) found that CPAP was associated with improved sleep-
related quality-of-life scores compared with controls (standard-
ized mean difference, 0.28 [95% CI, 0.14 to 0.42]; 13 trials, 2325
participants) (eFigure 27 in the Supplement). The sensitivity
analysis including only studies with mean or median baseline ESS
scores of 10 or greater found a similar effect size (0.33 [95% CI,
0.17 to 0.50]; 9 trials, 1709 participants) (eFigure 28 in the
Supplement).
Eight RCTs reported on the incidence of 1 or more cardio-
vascular and cerebrovascular events (eTable 29 in the Sup-
plement).63,70,76,93,97,99,103,107 Overall, too few cardiovascular
and cerebrovascular events were observed to draw conclusions.
Mandibular Advancement Devices
Included were 6 RCTs assessing the effect of MADs on health out-
comes (eTable 30 in the Supplement).98,105,114,116,121,122 Treatment
durations ranged from 4 to 12 weeks for most studies, while 1
lasted for only 1 week121 and 1 for 24 weeks.114 All studies included
Table 5. Summary of Accuracy of Diagnostic Tests for Obstructive Sleep Apnea, by PortableMonitor Type (Key Question 3)
No. and Design of Studies
Contributing to Summary
Range, %
Polysomnography AHI ≥5 Polysomnography AHI ≥15 Polysomnography AHI ≥30
Sensitivity Specificity AUC Sensitivity Specificity AUC Sensitivity Specificity AUC
Portable Monitor Type II
3 studies of diagnostic accuracy
(n = 160)33-35
88-96 50-84 86-90 85-94 77-95 89-94 64-86 98-100 85
Portable Monitor Type III
1 systematic review
of 19 studies (n = 1507)36
and 2 newer studies
of diagnostic accuracy (n = 184)37,38
87-96 60-76 89-96 49-92 79-95 85-97 50-97 90-93 86-99
Portable Monitor Type IV
1 systematic review
of 70 studies (n = 6873)21
and 11a newer studies
of diagnostic accuracy (n = 1358)30,39-49
65-100 35-100 NRb 7-100 15-100 NRc NRd NRe NRf
Abbreviations: AHI, apnea-hypopnea index (events/h); AUC, area under the
curve; NR, not reported.
a Three included studies of type IV portable monitors did not contribute results
for the AHI thresholds in this table.50-52
b The 2011 systematic review did not report the range of AUC values
for the 2007 technology assessment and articles newly included in the
2011 review. The AUC values among the studies newly identified since
the 2011 review ranged from 59 to 94.
c The 2011 systematic review did not report the range of AUC values for the
2007 technology assessment and articles newly included in the 2011 review.
The AUC values among the studies newly identified since the 2011 review
ranged from 89 to 96.
d The 2011 systematic review did not report the range of sensitivity values for
the 2007 technology assessment and articles newly included in the 2011
review. The sensitivity values among the studies newly identified since the
2011 review ranged from 59 to 100.
e The 2011 systematic review did not report the range of specificity values for
the 2007 technology assessment and articles newly included in the 2011
review. The specificity values among the studies newly identified since the
2011 review ranged from 71 to 100.
f The 2011 systematic review did not report the range of AUC values
for the 2007 technology assessment and articles newly included in the
2011 review. The AUC values among the studies newly identified since
the 2011 review ranged from 73 to 95.
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participants with mild to moderate OSA, and 3 also included par-
ticipants with severe OSA.105,116,121
Among the 4 trials that reported on mortality over 1 to 12
weeks,98,116,121,122 3 reported no deaths in any participants and 1 re-
ported 1 death in the group that received no treatment.116 Five in-
cluded trials reportedat least 1quality-of-lifemeasure.98,105,114,116,122
All 5 used the SF-36; 2 also used the SAQLI,105,122 and 2 also used
theFOSQ.98,122Overall, resultsweremixed,with somestudies find-
ingnosignificantbenefitsofMADs for improvingqualityof life,105,114
some reporting possible benefits for some measures or subscales
but not others,98,116 and some reporting benefits for some overall
quality-of-life scores.122Becauseof inconsistency, imprecision, and
heterogeneity of reporting, findingswere insufficient tomake con-
clusions about the potential benefits of MADs for improving qual-
ity of life.
Airway Surgery and Bariatric Surgery
Although 5 of the 6 RCTs included in KQ4 that evaluated surgical
treatments reported some information about at least 1 health out-
come, the trials provided limited evidence to determine whether
treatments improve health outcomes. The RCT (n = 60) that
compared bariatric surgery with a conventional weight loss pro-
gram in people with severe OSA125 reported greater improvement
in quality of life measured by the SF-36 physical component score
for those randomized to bariatric surgery at 2 years (between-
group difference, 9.3 [95% CI, 0.5 to 18.0]); however, there was
no significant difference between groups in the change from
baseline SF-36 mental component score (between-group differ-
ence, −0.3 [95% CI, −5.3 to 4.8]).125 Further details on the results
of trials that evaluated surgical interventions are provided in the
eResults in the Supplement.
Weight Loss, Diet, and Exercise Interventions
Six RCTs evaluated weight loss programs (eTable 27 in the
Supplement).129-138 Four RCTs (with a total of 45 participants) as-
sessedmortality; 3 reported no deaths in any group over 9 to 208
weeks,130,132,133 and 1 reported 1deathat 52weeks.136 FourRCTsas-
sessedqualityof life (eTable31 in theSupplement).129,133,135,136Over-
all, findingsweremixed, and too fewstudies reported results for the
same intervention and comparison using similar outcome mea-
sures to draw conclusions.
Association BetweenObstructive Sleep Apnea
and Health Outcomes
Key Question 6. Is there an association between AHI and health
outcomes?
Included were 11 prospective cohort studies (described in
12 articles) that assessed the association between AHI and
health outcomes (eTable 32 in the Supplement).12,143-153 All of
them focused on community-based participants; 1 also enrolled
some participants from a sleep clinic.12 Three studies analyzed
participants from the Sleep Heart Health Study,148,149,151 a cohort
of men and women 40 years or older recruited from other cohort
studies between 1995 and 1998. Two studies evaluated the
Wisconsin Sleep Cohort Study,145,150 a random sample of state-
employed adults 30 to 60 years of age. Two articles reported
data from the Busselton Health Study for different durations
of follow-up.152,153
Six studies reported the association with al l-cause
mortality,144,145,147,150-1533withcardiovascularmortality,12,150,1512with
cardiovascular events,12,148 and 1 each with cancer-related
mortality,145 stroke,149 cognitive decline,143 and cognitive impair-
mentordementia.146Nineof 11wereconducted in theUnitedStates.
Most studies followeduppatients for8 to 14years; follow-up ranged
from a mean of 3.4 years144 to 22 years.145 Three studies included
only men; half of the studies included between 45% and 56%
women. Mean BMI ranged from 26 to 30 in most studies. Partici-
pantsweregenerally untreated forOSA, or analyseswere run toex-
clude those whowere treated.
Six studies evaluated AHI as a predictor of all-cause
mortality.144,145,147,150-153Samplesizesrangedfrom289147 to6 294.151
Meandurationof follow-up ranged from3.4144 to20years.153Mean
age ranged from 48150 to 78 years.147 In multivariable analyses, all
6 studies reported that participantswith severe ormoderate to se-
vere OSA at baseline had a higher risk of death. Variables included
in the models are detailed in eTable 33 in the Supplement. Briefly,
all included age and somemedical conditions in the final model; all
considered BMI (although it did not remain in the final model in 1
study);most includedsmoking,sex, race,hypertensionorbloodpres-
sure, anddiabetes. Comparingmortality for patientswith severeor
moderate to severe OSA vs controls, meta-analysis found anHR of
2.07 (95% CI, 1.48 to 2.91) (Figure 3). Two studies150,151 assessed
whethermoderate (AHI 15 to <30) ormild (AHI 5 to <15) OSA levels
are associated with mortality; neither found a statistically signifi-
cant association (Figure 3).
Two studies reported evidence for subgroups—either by sex
and age151 or by presence of sleepiness.147 The former used the
Sleep Heart Health Study data (n = 6294) and reported that the
association between an AHI of 30 or greater and mortality was
statistically significant for men 70 years or younger (adjusted HR,
2.09 [95% CI, 1.31 to 3.33]) but not for men older than 70 years
(HR, 1.27 [95% CI, 0.86 to 1.86]) or for women of any age (HR,
1.40 [95% CI, 0.89 to 2.22]).151 The latter found that the associa-
tion between AHI of 20 or greater and death was limited to those
with excessive daytime sleepiness (determined by self-report of
having a problem with feeling sleepy or struggling to stay awake
during the daytime more than 3 or 4 times a week) but was not
significant for those without excessive daytime sleepiness (HR,
2.28 [95% CI, 1.46 to 3.57] vs HR, 0.74 [95% CI, 0.39 to 1.38])
compared with a reference group with AHI less than 20 and no
excessive daytime sleepiness.
Three studies evaluated the association between AHI and car-
diovascular mortality.12,150,151 Sample sizes ranged from 1522150 to
6294.151 Mean duration of follow-up ranged from 8.2151 to 13.8
years.150 Mean age ranged from 48150 to 63151 years. In multivari-
able analyses, all 3 studies reported that participants with severe or
moderate to severe OSA at baseline had a higher risk of cardiovas-
cular death (eFigure 29 in the Supplement), with HRs of 1.7 (95%
CI, 1.1 to 2.5) (for men only in the Sleep Heart Health Study),151 2.9
(95% CI, 1.1 to 7.3), and 5.9 (95% CI, 2.6 to 13.3).150 Variables
included in themodels are detailed in eTable 33 in the Supplement.
Briefly, all of them included age, BMI, smoking, and multiple medi-
cal conditions or used matching for age and BMI. Two of 3 included
alcohol use, blood pressure, and cholesterol level.
A single included study evaluated the association between AHI
and the incidence of each of the following outcomes: cancer-
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related mortality,145 nonfatal cardiovascular events,12 heart
failure,148 coronary heart disease,148 stroke,149 cognitive impair-
ment or dementia,146 and cognitive decline143 (eFigure 30 in the
Supplement). Overall, findings for these outcomes were imprecise,
consistency was unknown (with a single study for each), and evi-
dence was often limited by risk of bias (especially risk of residual
confounding).
Harms of Screening or Diagnostic Testing
Key Question 7a. Are there harms associated with screening or di-
agnostic testing for OSA?
Key Question 7b. Do the harms of screening or diagnostic testing
differ for subgroups defined by age, sex, or BMI?
No eligible studies were identified.
Harms of Treatment
Key Question 8a. Are there harms associated with treatment
of OSA?
Key Question 8b. Do the harms of treatment differ for subgroups
defined by age, sex, BMI, or OSA severity?
Reportingofharms in the included studieswas sparse. Twenty-
two of the RCTs included in KQ4 reported harms associated with
treatments for OSA: 9 trials of CPAP,66,70,75,88,91,92,101,105,108 8 of
MADs,105,114-122 1 of a very low energy diet,132 4 of airway surgical
treatments,123,124,126,128and1ofbariatric surgery (eTables35through
38 in the Supplement).125
Continuous Positive Airway Pressure
Of the9 includedRCTs,most enrolled fewer than 100participants;
1 trial91 enrolled 281, and the Apnea Positive Pressure Long-term
Efficacy Study (APPLES)70 enrolled 1098. Most of the studies
followed up patients for 8 to 12 weeks. Overall, 2% to 47% of par-
ticipants in trials reporting any harms had specific adverse events
whileusingCPAP. Ingeneral, harmswere likely short-livedandcould
be alleviated with discontinuation of CPAP or additional interven-
tions. These harms included oral or nasal dryness, eye or skin irrita-
tion, rash, epistaxis, and pain.
Mandibular Advancement Devices
Of the 8 included RCTs,105,114-116,118,120-122 study durations
ranged from 4 to 24 weeks. Across studies that reported any
discontinuation because of adverse events, 7% of patients
using MADs discontinued use, compared with 1% of control
patients.105,116,122 The most commonly reported symptoms that
occurred more often in active MAD study groups were oral
dryness,105,114,115,122 excess salivation105,114,115,117,122 (although 1
study reported a higher rate of excessive salivation in the sham
MAD group than in the active MAD group115), and oral mucosal,
dental, or jaw symptoms.
Airway Surgery and Bariatric Surgery
Five trials reported harms of surgical treatment: 1 each of single-
session soft palate radiofrequency surgery,123 temperature-
controlled radiofrequency tissue ablation,128 uvulopalatopharyn-
goplasty,124 laser-assisted uvulopalatoplasty,126 and bariatric
surgery.125 Reported harms included postoperative bleeding;
rehospitalization; difficulty speaking, breathing, drinking, opening
the mouth, and swallowing; change in vocal quality; hematomas;
ulcerations; infections; temporary nasal regurgitation; pain; and
rehospitalization after bariatric surgery because of an acute proxi-
mal gastric pouch dilation that required additional surgery (eTable
38 in the Supplement).
Figure 3. Association Between Apnea-Hypopnea Index and All-CauseMortality, by OSA Severity
Weight,
%
Favors
Group 1
Favors
Group 2
0.5 101.0
Hazard Ratio (95% CI)
No. of Deaths/
Total No. (%)
Group 1
No. of Deaths/
Total No. (%)
Group 2Source
Severe OSA
Follow-up, y
Hazard Ratio
(95% CI)
Apnea-Hypopnea
Index Comparison,
Group 1 vs Group 2
13.4712/63 (19.0) 46/1157 (4.0)Young et al,150 2008 13.8 2.70 (1.29-5.65)≥30 vs <5
31.2786/341 (25.2) 477/3429 (13.9)Punjabi et al,151 2009 8.2 1.46 (1.14-1.86)≥30 vs <5
Moderate OSA
4.046/82 (7.3) 46/1157 (4.0)Young et al,150 2008 13.8 1.30 (0.51-3.29)15 to <30 vs <5
95.96165/727 (22.7) 477/3429 (13.9)Punjabi et al,151 2009 8.2 1.17 (0.97-1.42)15 to <30 vs <5
22.6635/42 (83.3) 59/119 (49.6)Gooneratne et al,147 2011 13.8 2.28 (1.46-3.57)≥20 and EDS vs
<20 and no EDS
20.2225/209 (12.0) 155/2296 (6.8)Ensrud et al,144 2012 3.4 1.74 (1.04-2.90)≥30 vs <30
12.3810/18 (55.6) 54/294 (18.4)Marshall et al,153 2014 20 4.20 (1.91-9.24)≥15 vs <5
100.0Subtotal (I2 = 57.8%, P = .05) 2.07 (1.48-2.91)
100.0Subtotal (I2 = 0.0%, P = .83) 1.17 (0.97-1.42)
Mild OSA
28.9416/220 (7.3) 46/1157 (4.0)Young et al,150 2008 13.8 1.50 (0.80-2.81)5 to <15 vs <5
71.06319/1797 (17.8) 477/3429 (13.9)Punjabi et al,151 2009 8.2 0.93 (0.80-1.08)5 to <15 vs <5
100.0Subtotal (I2 = 52.7%, P = .15) 1.07 (0.70-1.63)
Effect sizes in the figure are hazard ratios. Size of data markers reflects their
relative contributions to the pooled effect size (largely because of their sample
sizes). Obstructive sleep apnea (OSA) severity category definitions follow those
provided in Table 1. For themeta-analysis of severe OSA, 2 studies were
included that provided data for participants with severe OSA combined
with some or all participants with moderate OSA (Marshall et al153 and
Gooneratne et al147). EDS indicates excessive daytime sleepiness.
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Weight Loss, Diet, and Exercise Interventions
The single weight loss study that reported harms compared a very
low energy diet with usual diet over 9weeks.132 In the very low en-
ergy diet group, fewer than 10% of patients reported each of the
following: constipation, dizziness, gout, and dry lips.
Discussion
The summary of findings is presented in Table 6. No eligible stud-
ies directly evaluated the effectiveness or adverse outcomes of
Table 6. Summary of Evidence for Screening and Treatment of Obstructive Sleep Apnea
Key Question
and Topic
No. of Studies
(Study Design) No. of Participants
Summary of Main Findings
(Including Consistency
and Precision) Applicability
Limitations (Including
Reporting Bias)
Quality of
Evidence
1: Benefits
of screening
0 (NA) NA No studies were identified
that directly evaluated the
benefits of screening
compared with no screening.
NA NA NA
2: Accuracy
of prediction
tools or
screening
questionnaires
3 (cross-sectional) 1220 (with
polysomnography
reference standard)
The only screening approach
with 2 eligible studies
reporting adequate accuracy
was the MVAP followed by
home portable monitor
testing. For detecting severe
OSAS (AHI ≥30 and ESS score
>10), AUCs were 0.80 (95%
CI, 0.78 to 0.82) and
0.83 (95% CI, 0.77 to 0.90);
these findings were
consistent and precise.
Populations with high
prevalence of OSA and
OSAS; studies included
Medicare recipients
and adults with
hypertension
Studies of MVAP
oversampled high-risk
participants and those with
OSA and OSAS. Data were
limited by risk of spectrum
bias. No studies
prospectively evaluated
screening tools to report
calibration or clinical
utility. Reporting bias
not detected.
Fair
3: Diagnostic
accuracy
and reliability
of portable
monitors
21 (2 systematic
reviews and 19
primary studies
evaluating portable
monitors published
after their literature
search cutoffs)
10 624 Best evidence is from
good-quality systematic
reviews that reported
sensitivities 93%-96% for
type III portable monitors
and ≥85% for type IV
portable monitors for
detecting any OSA (AHI ≥5).
Corresponding specifities
were 60% (in-home) and
76% (in-laboratory) for
type III portable monitors
and ranged from 50% to
100% for type IV portable
monitors. Sensitivity
decreased and specificity
increased for detecting
moderate or greater OSA
(AHI ≥15) or severe OSA
(AHI ≥30). Wide ranges for
sensitivity and specificity
were reported across studies
(eg, type III: 49%-92% and
79%-95%; type IV: 7%-100%
and 15%-100%, respectively,
for polysomnographic AHI
≥15). Findings were
reasonably consistent for
type II and III portable
monitors, inconsistent for
type IV portable monitors,
and imprecise.
Those suspected of
having OSA; referral
populations
Small total sample size
(type II), missing data
(types II and IV), and some
lack of independent scoring
of portable monitor and
polysomnography results
(types II and IV).
Heterogeneity of scoring
criteria or methods and
portable monitor AHI
cutpoints (type IV) and
heterogeneity of results
across portable monitor
settings (laboratory, home)
and for more severe OSA
(type III). Reporting bias
not detected.
Fair to
Good
4: Benefits of
treatment for
intermediate
outcomes:
AHI, ESS
score, or
blood
pressure
76 (RCTs) 7541 CPAP was associated with
reduction of AHI (WMD,
−33.8 [95% CI,
−42.0 to −25.6]; 13 trials,
543 participants), excessive
sleepiness (ESS WMD, −2.0
[95% CI, −2.6 to −1.4]; 22
trials, 2721 participants),
diurnal SBP (WMD, −2.4
[95% CI, −3.9 to −0.9]; 15
trials, 1190 participants),
and diurnal DBP (WMD, −1.3
[95% CI, −2.2 to −0.4]; 15
trials, 1 190 participants)
compared with sham. MADs
and weight loss programs
were also associated with
reduced AHI and excessive
sleepiness; effect sizes were
generally smaller than those
for CPAP.a
Referral population
with known OSA
Most trials were ≤12 wk;
statistical heterogeneity in
some meta-analyses. For
ESS, potential bias from
self-report and construct
validity has been
questioned. Just 1 trial for
bariatric surgery and for
each of 5 different airway
surgical treatments
(sample sizes, 32 to 67).
Reporting bias
not detected.
Fair to
Good
(continued)
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screeningcomparedwithnoscreening.Potentialharms includeover-
diagnosisandovertreatment forasymptomaticpeople (withAHI5)
who would never have developed symptoms of or problems from
OSA, costs, andadditional testing (eg, futurepolysomnographies to
followuppatientsover time). Furthermore, noeligible studieswere
found that evaluated the effect of screening on psychological out-
comes such as distress due to labeling or stigma.
Very few eligible studies evaluated the accuracy of question-
naires or prediction tools for distinguishing people in the general
populationwhoaremoreor less likely tohaveOSA.Theonly screen-
ingapproachwithat least2 includedstudies suggestingpossible ac-
curacywas theMVAPscore followedby in-homeportablemonitor-
ing for detecting severe OSAS. Although this approach may have
potential for screening, theevidencewas limitedbypotential spec-
trumbias,154-158withoversamplingofhigh-riskparticipantsandthose
with OSA and OSAS, whichmay substantially overestimate the ac-
curacy that would be achieved in the general population. Spec-
trum bias occurs when heterogeneity of test performance exists
Table 6. Summary of Evidence for Screening and Treatment of Obstructive Sleep Apnea (continued)
Key Question
and Topic
No. of Studies
(Study Design) No. of Participants
Summary of Main Findings
(Including Consistency
and Precision) Applicability
Limitations (Including
Reporting Bias)
Quality of
Evidence
5: Benefits of
treatment for
health
outcomes
50 (RCTs) 6191 Evidence on most health
outcomes was limited; too
few trials reported them or
too few events occurred to
make conclusions for most
health outcomes (eg,
mortality, cardiovascular
events, motor vehicle
crashes). However, CPAP was
associated with improvement
in sleep-related quality of
life, albeit with a small effect
size (Cohen d, 0.28 [95% CI,
0.14 to 0.42]; 13 trials,
2325 participants).
Referral population
with known OSA
Study durations may be
insufficient to determine
benefit for many health
outcomes; small number of
total events observed
across studies (eg, for
mortality, motor vehicle
crashes, stroke, and
cardiovascular events).
Reporting bias not
detected.b
Fair
6: Association
between AHI
and health
outcomes
11 (prospective
cohort)
26 954 Increased risk of mortality
for people with severe OSA
(pooled HR, 2.07 [95% CI,
1.48 to 2.91]; 5 studies,
11 003 participants). Risk of
cardiovascular mortality also
increased (HRs from 2.9
[95% CI, 1.1 to 7.5] to 5.9
[95% CI, 2.6 to 13.3].
Findings were consistent and
precise for all-cause
mortality; consistent but
imprecise for cardiovascular
mortality.c
General population Risk of residual
confounding (eg, due to
physical activity, diet).
Single study for all other
outcomes (eg,
cancer-related mortality,
stroke, CHD). Reporting
bias not detected.
Fair to
Good
7: Harms of
screening or
diagnostic
testing
0 (NA) NA No studies were identified
that directly evaluated the
harms.
NA NA NA
8: Harms of
treatment
22 (RCTs) 2496 Common adverse effects of
CPAP included oral or nasal
dryness, eye or skin irritation,
rash, epistaxis, and pain;
common adverse effects of
MADs included oral dryness,
excess salivation, mucosal
erosions, or pain (mucosal,
dental, or jaw). Findings
were consistent but
imprecise for CPAP,
inconsistent and imprecise
for MADs, and of unknown
consistency for other
treatments (single study for
each).
Referral population
with known OSA
High heterogeneity in
reporting and findings for
CPAP and MADs. Singe
studies and small sample
sizes for surgical
interventions and weight
loss programs. Reporting
bias not detected.
Fair
Abbreviations: AHI, apnea-hypopnea index; AUC, area under the curve;
CHD, coronary heart disease; CPAP, continuous positive airway
pressure; DBP, diastolic blood pressure; ESS, Epworth Sleepiness Scale;
HR, hazard ratio; MAD, mandibular advancement device; MVAP, multivariable
apnea prediction; NA, not available; OSA, obstructive sleep apnea;
OSAS, obstructive sleep apnea syndrome; RCT, randomized clinical trial;
SBP, systolic blood pressure; WMD, weightedmean difference.
a The total number of trials reporting each outcome for CPAP is more than the
number that contributed to the data in this column because the CPAP vs
control data were not entered. Rather, the focus was on the CPAP vs sham
data. However, evidence from both comparator groupings was considered
in the assessments.
b Transient ischemic attacks: few events across 3 RCTs (CPAP vs comparators:
total of 4 vs 7 combining all trials); strokes: few events across 4 RCTs
(CPAP vs comparators: 3 vs 3 combining all trials). Trial durations were
12 weeks, 24 weeks, 1 year, and 4 years (median follow-up). Myocardial
infarction: few events across 5 RCTs (5 vs 8 combining all trials); incident
angina or unstable angina: few events across 4 RCTs (4 vs 9 combining all
trials); incident atrial fibrillation: 3 RCTs (12 vs 20 events combined).
c Two of the publications used data from the same cohort, theWisconsin Sleep
Cohort Study; those participants were not double counted here (and only 1
of the publications was used in themeta-analysis).
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across subgroupsandstudiespreferentially sample (intentionallyor
unintentionally) froma subgroupof the target population. None of
the included studies evaluatingMVAPprospectivelymeasuredcali-
bration, often assessed by plotting the predicted risk vs an ob-
served event rate,31 and none assessed clinical utility for improving
health outcomes.
This review included fewer studiesevaluatingquestionnairesor
clinicalprediction tools thansomepreviouslypublished reviewsand
guidelines,1,21,159 primarily because of the requirement that studies
enroll asymptomatic adults or persons with unrecognized symp-
toms ofOSA; referral populations (eg, to sleep clinics) were not eli-
gible. The focusofprevious reviewsandguidelineswasgenerallyon
diagnostic testing (of adults with symptoms suggestive of disor-
dered sleep) rather than on screening (of asymptomatic people or
thosewith unrecognized symptoms). Nevertheless, those reviews
and guidelines generally reported lowoverall quality or strength of
evidence for questionnaires and prediction tools.
Related to accuracy of diagnostic tests, there was limited evi-
denceevaluating type II portablemonitors. For type III and IVmoni-
tors, existing literature revealed some inconsistency, with wide
rangesofsensitivityandspecificity,especially for single-channel type
IV monitors for detecting moderate to severe OSA. Nevertheless,
many studies reported moderate to high positive likelihood ratios
(>5) andmoderate to lownegative likelihood ratios (<0.2), andpre-
vious reviews and guidelines concluded thatmoderate-quality evi-
dence shows that type III and IVmonitors are “generally accurate to
diagnose OSA, but have a wide and variable bias in estimating the
actual AHI.”21,159 Evidence for type IV portable monitors is limited
by inconsistency and imprecision. In addition, unlike other types of
portablemonitors, type IVmonitors are limited by their inability to
differentiate obstructive and central events.
This review foundconsistent evidence fromRCTs thatCPAPef-
fectively reducesAHI to normal (<5) or near-normal levels, reduces
excessivesleepiness,andreducesbloodpressure.However, theclini-
cal significance of mean reductions of 2 points on the ESS and 2 to
3 points for blood pressure measures is somewhat uncertain. For
sleepiness, thedata suggest a clinically significant reduction inmost
included trials because85%of the trials in themeta-analysis forESS
that had mean baseline ESS scores of 10 or greater (indicating ex-
cessivedaytimesleepiness) reportedmeanend-pointESS scores in
the normal range of less than 10160,161 for the CPAP groups (mean
end-point ESS score across studies was <8). However, the thresh-
old for a clinically significant change in ESS score is somewhat un-
certain. Although a recent review noted that experts consider a
1-point change clinically significant,21 other sources suggest that a
greater change, of at least 3 or 4 points, should be the clinically sig-
nificant threshold. For example, some trials that useESS score as an
outcome have considered a change of 4 or more points to be clini-
cally significant for their sample size calculations or interpretation
of findings.162-164 Regardless of what constitutes a clinically signifi-
cant change,potential bias fromthesubjectivenatureof theESS re-
mains, and some authors have raised concerns about its construct
validity (ie, uncertainty regarding whether it is an accurate mea-
sure of sleepiness).165-167
For bloodpressure reduction, some authors suggest that a dif-
ference of more than 9/10 (systolic/diastolic) mm Hg is clinically
meaningful for individuals.168-170 However, across a population,
guidelines have suggested that reductions of 2 to 3mmHg for sys-
tolic bloodpressure could result in a significant reduction in cardio-
vascularmortality (by4%-5%forcoronaryheartdiseaseand6%-8%
for stroke).171
MADs and weight loss programs also reduce AHI and exces-
sive sleepiness, although themagnitudes of effects were generally
less than with CPAP, and blood pressure reduction was not estab-
lished. Although this reviewdid not evaluate head-to-head studies
(eg,directly comparingMADswithCPAP), previous comparativeef-
fectiveness reviewsexamininghead-to-head trials reportedsmaller
effect sizes forMADs than forCPAP for reducingAHI.21 Evidenceon
surgical treatments was limited by unknown consistency and im-
precision, because only a single RCT evaluated each surgical tech-
nique studied.
Evidence on most health outcomes was limited; too few RCTs
reportedthemortoofeweventsoccurredtomakeconclusionsabout
the effectiveness for reducing mortality, cardiovascular events, or
motor vehicle crashes. However, the meta-analysis for sleep-
relatedqualityof life foundasignificantbenefit forCPAP, albeitwith
a small effect size.
Reportingof harms fromtreatment in the included studieswas
sparse. In general, the adverse events related to CPAP treatment
were likely short-lived and could be alleviatedwith discontinuation
of CPAP or additional interventions. No included studies reported
on psychosocial harms of treatment, such as marital stress due to
disruption of partner sleeping (eg, because of the noise of CPAP).
Adverseeffectsmay limit adherence to treatment.Awide range
of adherence to CPAPusage recommendations has been reported,
ranging from about 30% to 85%.172 A systematic review reported
that cohort studies with multivariable analyses for predictors of
nonadherence showed that 14% to 32% of patients discontinued
CPAP over 4 years and that patients used CPAP for an average
of 5 hours per night; data were too limited to provide adherence
rates for MADs.21 A recent Cochrane systematic review of 33 stud-
ies (2047participants) found low-tomoderate-qualityevidencethat
3 types of interventions can increase CPAP usage in CPAP-naive
participants.172However, theynotedthat trialsdidnotassesspeople
who have struggled to adhere, and the effect of improved CPAP
usage on health outcomes remains unclear.
Consistent evidence from prospective cohort studies that fo-
cused on community-based participants supports the association
betweenAHI andall-causemortality. Peoplewith severe (AHI30)
or moderate to severe (AHI15) OSA had a hazard ratio for death
of 2.07 comparedwith controls when pooling data frommultivari-
able analyses. There was also consistent evidence showing that
peoplewith severe ormoderate to severe OSA have increased car-
diovascular mortality. The cohort studies controlled for many po-
tential confounders,but residual confoundingattributable tohealth-
related factors associatedwith OSA (eg, physical activity, diet) and
generally not accounted for is possible.
This reviewhad limitations.Theability todescribe thedirectevi-
dence on the effectiveness or harms of screening was inadequate,
because no studies comparing screened and unscreened popula-
tionswere identified. Therefore, literaturewas reviewed thatmight
establish an indirect chainof evidence frommultiplequestions that
link screening to health outcomes. For the first question in that in-
direct pathway (KQ2), therewas limited evidence that one screen-
ingapproachmightbeuseful to screen for severeOSAS,but theevi-
dence was limited by potential spectrum bias, and no studies
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prospectively assessed calibration or clinical utility for improving
health outcomes. In addition, this review did not evaluate the ac-
curacy of individual physical examination findings. Questionnaires
or clinical prediction toolswere required tohavemultiple factorsbe-
cause previous systematic reviews have found limited utility of in-
dividual findings. A recent review of clinical examination accuracy,
which was not limited to asymptomatic patients or those with un-
recognized symptoms, found that (among individual symptoms or
signs) themostuseful observation for identifyingpatientswithOSA
was nocturnal choking or gasping, imparting a small increase in the
likelihood of disease (summary likelihood ratio, 3.3 [95% CI, 2.1 to
4.6] when the diagnosis was established by AHI10).1 The review
found that many symptoms and signs provide limited information
in determining the likelihood of OSA.1
Conclusions
There is uncertainty about the accuracy or clinical utility of all po-
tential screening tools.Multiple treatments forOSAreduceAHI,ESS
scores, andbloodpressure.TrialsofCPAPandother treatmentshave
not established whether treatment reduces mortality or improves
most other health outcomes, except for modest improvement in
sleep-related quality of life.
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